Arrowhead Research Corporation(ARWR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ARWR Arrowhead Research Corporation

交易中 11-13 13:31:20 EST

46.89

-0.26

-0.55%

最高48.29	最低44.52	成交量150.27万
今开47.68	昨收47.15	日振幅8.00%
总市值66.05亿	流通市值57.21亿	总股本1.41亿
成交额6,972万	换手率1.23%	流通股本1.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ARWR","market":"US","secType":"STK","nameCN":"Arrowhead Research Corporation","latestPrice":46.89,"timestamp":1794594675256,"preClose":47.15,"halted":0,"volume":1502661,"delay":0,"changeRate":-0.005514316012725303,"floatShares":122000000,"shares":140857021,"eps":-2.28382,"marketStatus":"交易中","change":-0.26,"latestTime":"11-13 13:31:20 EST","open":47.68,"high":48.29,"low":44.52,"amount":69720104.43936,"amplitude":0.079958,"askPrice":47.01,"askSize":112,"bidPrice":46.86,"bidSize":27,"shortable":3,"etf":0,"ttmEps":-2.28382,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1794603600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":740203200000,"exchange":"NASDAQ","adjPreClose":47.15,"preHourTrading":{"tag":"盘前","latestPrice":47.4,"preClose":47.15,"latestTime":"09:23 EST","volume":1646,"amount":77173.54287599999,"timestamp":1794579798976,"change":0.25,"changeRate":0.005302,"amplitude":0.024178},"postHourTrading":{"tag":"盘后","latestPrice":46.22,"preClose":47.15,"latestTime":"19:44 EST","volume":63446,"amount":2985083.7891,"timestamp":1794530660221,"change":-0.93,"changeRate":-0.019724,"amplitude":0.044282},"volumeRatio":0.722914,"impliedVol":0.6236,"impliedVolPercentile":0.4861},"requestUrl":"/m/hq/s/ARWR","defaultTab":"news","newsList":[{"id":"1178831846","title":"一天暴涨132%！PepGen这份试验数据有多强？","url":"https://stock-news.laohu8.com/highlight/detail?id=1178831846","media":"明星股动态","labels":["dataReport","videos"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178831846?lang=zh_cn&edition=full","pubTime":"2026-11-11 16:21","pubTimestamp":1794385295,"startTime":"0","endTime":"0","summary":"","market":"hk","thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/5264.webp","type":0,"news_type":0,"thumbnails":["https://news-video-sg.skytigris.cn/videos/covers/5264.webp"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,videos","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPT","PEPG","ARWR","SRPU","DYN","XBI"],"isVideo":true,"video":{"duration":110,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/5264/render_5264_1794384879354.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/5264.webp","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/5264/tts/voiceover_0b4223c60850107369d8bed0.mp3","isAI":true},"gpt_icon":0},{"id":"1103682283","title":"异动解读｜Arrowhead Research Corporation盘中下跌17.27%，财报前业绩预期承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1103682283","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103682283?lang=zh_cn&edition=full","pubTime":"2026-11-10 00:31","pubTimestamp":1794241865,"startTime":"0","endTime":"0","summary":"11月10日，Arrowhead Research Corporation盘中下跌17.27%，报48.115美元/股，成交额1.77亿美元。此前机构整体观点虽偏积极，平均评级仍为买入、目标价在107.92美元附近，但临近财报时点，市场交易重心更集中于短期业绩承压与亏损扩大的兑现风险。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报临近，Arrowhead盘中跳水承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178201324","title":"财报前瞻 | Arrowhead Research Corporation本季度营收预计降68.25%，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1178201324","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178201324?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:21","pubTimestamp":1793838074,"startTime":"0","endTime":"0","summary":"Arrowhead Research Corporation将于2026年11月12日（盘后）发布最新财报，市场关注收入波动与研发投入节奏对盈利路径的影响。市场一致预期本季度公司营收为5,583.83万美元，同比下降68.25%；调整后每股收益为-1.59美元，同比下降5.59%，同时EBIT预计为-2.12亿美元，同比下降887.78%。目前市场侧一致预期未提供本季度毛利率与净利润或净利率的明确预测区间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | Arrowhead Research Corporation本季度营收预计降68.25%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118731380","title":"异动解读｜Arrowhead Research Corporation盘前上涨6.66%，Plozasiran获纳入FDA快速审评试点","url":"https://stock-news.laohu8.com/highlight/detail?id=1118731380","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118731380?lang=zh_cn&edition=full","pubTime":"2026-10-14 20:06","pubTimestamp":1791979602,"startTime":"0","endTime":"0","summary":"10月14日，Arrowhead Research Corporation盘前上涨6.66%，报62.39美元/股，成交额163.65万美元。消息面上，公司此前披露，FDA已将Plozasiran治疗重度高甘油三酯血症的补充新药申请纳入Split Real Time Application Review试点项目。该计划旨在缩短补充申请从完整递交到最终审批的时间；入选后可获得6个月优先审评，而非10个月标准审评，且公司无需动用原计划使用的优先审评券。此前Plozasiran已在两项Ⅲ期研究中达到主要和次要终点，并计划于年底前提交补充申请，监管提速预期成为股价催化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Arrowhead盘前上涨，Plozasiran获FDA快速审评","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140477807","title":"异动解读｜Arrowhead Research Corporation盘前下跌6.35%，报66.86美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1140477807","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140477807?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:50","pubTimestamp":1790758255,"startTime":"0","endTime":"0","summary":"9月30日，Arrowhead Research Corporation盘前下跌6.35%，报66.86美元/股，成交额2542.03美元。Arrowhead Research Corporation所在的生物科技行业中，个股中，Moderna涨0.05%，安进涨0.24%，Iovance Biotherapeutics跌1.31%，艾伯维公司涨0.21%，Natera涨0.73%。Arrowhead Pharmaceuticals, Inc.开发基于RNA干扰机制的药物，通过沉默致病基因治疗疑难杂症，目前有18个候选药物处于早期至晚期临床试验阶段。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184239030","title":"异动解读｜Arrowhead Research Corporation盘中下跌6.92%，报66.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184239030","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184239030?lang=zh_cn&edition=full","pubTime":"2026-09-24 00:13","pubTimestamp":1790180015,"startTime":"0","endTime":"0","summary":"9月24日，Arrowhead Research Corporation盘中下跌6.92%，报66.89美元/股，成交额4619.96万美元。Arrowhead Research Corporation所在的生物科技行业中，个股中，Moderna涨1.22%，Greenland Mines跌14.11%，安进跌1.24%，Viking Therapeutics涨1.0%，艾伯维公司跌0.16%。Arrowhead Pharmaceuticals, Inc.主要开发基于RNA干扰机制的药物，通过沉默致病基因来治疗疑难杂症，目前有18个候选药物处于1期至3期临床试验阶段。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137207724","title":"异动解读｜Arrowhead Research盘中下跌5.41%，双功能RNAi疗法interim数据措辞保守引发持续抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1137207724","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137207724?lang=zh_cn&edition=full","pubTime":"2026-09-17 02:11","pubTimestamp":1789582285,"startTime":"0","endTime":"0","summary":"9月17日，Arrowhead Research盘中下跌5.41%，报66.85美元/股，成交额1.9亿美元，延续前一交易日跌势。消息面上，公司于9月15日公布首款双功能RNAi疗法治疗混合型高脂血症的interim顶线临床数据，同步披露单剂量递增研究已推进至400毫克剂量水平，未见药物相关严重不良事件。尽管安全性信号积极，但公告仅提及\"初步疗效信号\"，措辞较为保守，投资者对疗效数据强度产生疑虑，获利回吐压力延续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"双功能RNAi数据措辞保守，股价承压回落","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117739534","title":"异动解读｜Arrowhead Research盘中下跌8.95%，双功能RNAi疗法interim数据公布后遭抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=1117739534","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117739534?lang=zh_cn&edition=full","pubTime":"2026-09-16 00:14","pubTimestamp":1789488889,"startTime":"0","endTime":"0","summary":"9月15日，Arrowhead Research盘中下跌8.95%，报73.55美元/股，成交额1.25亿美元。消息面上，公司于当日公布了首款双功能RNAi疗法治疗混合型高脂血症的interim顶线临床数据，并同步披露单剂量递增研究已推进至400毫克剂量水平、未见药物相关严重不良事件。尽管安全性信号积极，但公告仅提及\"初步疗效信号\"，措辞较为保守，投资者对疗效数据的强度或产生疑虑，引发获利回吐压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Arrowhead Research盘中下跌，双功能RNAi数据引发抛售","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136110326","title":"Arrowhead制药完成单剂量递增至400毫克，未见药物相关严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1136110326","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136110326?lang=zh_cn&edition=full","pubTime":"2026-09-15 19:32","pubTimestamp":1789471951,"startTime":"0","endTime":"0","summary":"Arrowhead制药——单剂量递增研究已推进至400毫克剂量水平，且未报告任何与药物相关的严重不良事件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","ARWR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120102288","title":"Arrowhead Pharmaceuticals公布首款双功能RNAi疗法治疗混合型高脂血症的 interim 顶线临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1120102288","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120102288?lang=zh_cn&edition=full","pubTime":"2026-09-15 19:31","pubTimestamp":1789471874,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals 日前揭晓了其针对混合型高脂血症的首款双功能RNAi治疗药物——interim顶线临床数据。这一消息引发了业界广泛关注，因为该疗法有望为血脂异常患者开辟全新的治疗路径。在数据发布中，Arrowhead 通过严谨的统计学分析，展示了药物在受试者中的安全性、耐受性以及初步疗效信号。Arrowhead 的研发管线亦因此备受瞩目，投资者对后续里程碑事件的推进抱以谨慎乐观态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","ARWR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117094130","title":"Arrowhead Pharmaceuticals：Plozasiran在III期研究中展现良好安全性与耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1117094130","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117094130?lang=zh_cn&edition=full","pubTime":"2026-08-30 23:33","pubTimestamp":1788103990,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals近日宣布，其研发的Plozasiran在III期临床研究中表现出令人满意的安全性和耐受性特征。这一积极的结果无疑为该公司在代谢疾病领域的布局注入了强心剂。值得关注的是，这项III期研究的数据进一步验证了Plozasiran作为潜在治疗方案的可行性。Plozasiran所呈现的有利安全谱，或将为特定疾病群体带来新的希望。随着研究数据的持续积累与解读，Plozasiran的临床应用前景正逐渐变得清晰。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116619525","title":"Arrowhead Pharmaceuticals拟于2026年底前凭优先审评券向美国FDA提交补充新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1116619525","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116619525?lang=zh_cn&edition=full","pubTime":"2026-08-30 23:32","pubTimestamp":1788103929,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals（股票代码：ARWR）宣布，计划于2026年底之前，借助优先审评券，向美国食品药品监督管理局（FDA）提交补充新药申请（sNDA）。这一举措标志着公司在推进其候选药物监管审批进程中迈出关键一步。优先审评券的运用，有望显著缩短FDA对新药申请的审评周期，从而加速产品走向市场的步伐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107393929","title":"箭头制药（Arrowhead Pharmaceuticals）公布三期Shasta-3和Shasta-4数据：Plozasiran显著减少重度高甘油三酯血症患者的急性胰腺炎事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1107393929","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107393929?lang=zh_cn&edition=full","pubTime":"2026-08-30 23:31","pubTimestamp":1788103875,"startTime":"0","endTime":"0","summary":"两项研究均采用随机、双盲、安慰剂对照设计，旨在评估Plozasiran对极高甘油三酯水平患者的治疗潜力。结果显示，与安慰剂组相比，接受Plozasiran治疗的患者群体中，急性胰腺炎事件的发生率呈现具有统计学意义的下降。这些结果表明，Plozasiran在重度高甘油三酯血症人群中具有可接受的风险-获益比。总而言之，Shasta-3和Shasta-4的积极结果，为Plozasiran的临床开发注入了强心剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","ARWR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178953219","title":"德国家族性乳糜微粒血症综合征（FCS）患者迎来新疗法：Redemplo®（Plozasiran）可有效降低甘油三酯","url":"https://stock-news.laohu8.com/highlight/detail?id=1178953219","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178953219?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:34","pubTimestamp":1786973661,"startTime":"0","endTime":"0","summary":"在德国，患有家族性乳糜微粒血症综合征的患者如今迎来了一项令人振奋的治疗新选择——Redemplo。这一创新药物旨在显著降低患者体内异常升高的甘油三酯水平，为这一罕见且棘手的代谢性疾病患者群体带来了新的曙光。Redemplo作为一种靶向RNA干扰疗法，通过精准抑制肝脏中APOC3基因的表达，从而有效调节脂质代谢，降低血浆甘油三酯浓度。随着Redemplo在德国正式可供使用，相关医疗体系也正积极整合这一新选项，力求在最短时间内将其纳入规范治疗流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4585","ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154955623","title":"Arrowhead制药计划在2026年底前使用优先审评券，为Plozasiran提交重度高甘油三酯血症补充新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1154955623","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154955623?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:01","pubTimestamp":1785873671,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals（股票代码：ARWR）宣布，该公司计划在2026年年底之前，利用一张优先审评券（Priority Review Voucher），为旗下药物Plozasiran提交针对重度高甘油三酯血症（Severe Hypertriglyceridemia）的补充新药申请（sNDA）。这一举动显示出该公司正加速推进其关键管线的监管审批进程。通过使用这一宝贵资源，Arrowhead希望缩短审评周期，使治疗方案更快惠及患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","ARWR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147562503","title":"Arrowhead制药完成全球3期Yosemite研究入组，探索Zodasiran治疗纯合子家族性高胆固醇血症","url":"https://stock-news.laohu8.com/highlight/detail?id=1147562503","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147562503?lang=zh_cn&edition=full","pubTime":"2026-07-27 19:31","pubTimestamp":1785151872,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals（股票代码：ARWR，中文名：Arrowhead Research Corporation）宣布，其针对Zodasiran治疗纯合子家族性高胆固醇血症的全球3期Yosemite研究已全面完成患者入组。这一里程碑标志着该候选药物在临床开发上迈出了关键一步，旨在为这一罕见且严重的遗传性脂质代谢疾病提供新的治疗选项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARWR","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125758170","title":"异动解读｜Arrowhead Research Corporation盘中上涨19.25%，核心管线Plozasiran后期试验数据亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=1125758170","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125758170?lang=zh_cn&edition=full","pubTime":"2026-07-22 21:39","pubTimestamp":1784727594,"startTime":"0","endTime":"0","summary":"7月22日，Arrowhead Research Corporation盘中上涨19.25%，报89.54美元/股，成交额1.14亿美元。消息面上，公司公布核心药物Plozasiran在两项关键后期临床试验Shasta-3和Shasta-4中成功达到主要终点，分别实现79%和81%的中位甘油三酯降低率；在高危患者群体中实现急性胰腺炎事件100%的风险削减，且安全性特征稳定，未出现新安全信号。Plozasiran此前已以商品名Redemplo获得欧盟上市许可，用于治疗家族性乳糜微粒血症综合征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141151307","title":"Arrowhead Pharmaceuticals股价盘前飙升18.1%，血脂药物达后期试验目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1141151307","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141151307?lang=zh_cn&edition=full","pubTime":"2026-07-22 20:52","pubTimestamp":1784724738,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals的股价在盘前交易时段大幅上涨18.1%，此前该公司宣布其研发的一款血脂药物在后期临床试验中成功达到了主要目标。\n这一积极进展显著提振了投资者信心，推动该公司股票在开盘前即录得强劲涨幅。该药物的成功标志着Arrowhead在心血管疾病治疗领域的研发取得了关键性突破。\n市场分析人士指出，后期试验目标的达成通常意味着药物距离最终获批上市更近一步，这为公司未来的商业化前景带来了明确利好。此次股价的剧烈反应，也反映了市场对该创新疗法潜在价值的认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ARWR","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119942739","title":"异动解读｜Arrowhead Pharmaceuticals盘前上涨8.64%，核心管线Plozasiran多项关键试验数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1119942739","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119942739?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:36","pubTimestamp":1784720197,"startTime":"0","endTime":"0","summary":"7月22日，Arrowhead Pharmaceuticals盘前上涨8.64%，报84.0美元/股，成交额6.85万美元。消息面上，公司公布旗下药物Plozasiran在两项关键临床试验Shasta-3和Shasta-4中分别实现79%和81%的中位甘油三酯降低率；同时该药物在高危患者群体中实现急性胰腺炎事件100%的风险削减，且未出现新的安全信号，安全性特征稳定。Plozasiran此前已以商品名Redemplo获得欧盟上市许可，用于治疗家族性乳糜微粒血症综合征。此次多项积极数据同步发布，进一步拓宽了该药物在心血管代谢疾病领域的适应症前景。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128819834","title":"Arrowhead Pharmaceuticals旗下Plozasiran展现一致安全性，未出现新安全信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1128819834","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128819834?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:33","pubTimestamp":1784719981,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals宣布，其研发中的药物Plozasiran在临床试验中持续展现出稳定的安全性特征，期间未观察到新的安全信号。这一结果进一步支持了该药物的开发前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","ARWR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arrowheadpharma.com","stockEarnings":[{"period":"1week","weight":-0.1794},{"period":"1month","weight":-0.1889},{"period":"3month","weight":-0.4558},{"period":"6month","weight":-0.385},{"period":"1year","weight":0.1383},{"period":"ytd","weight":-0.2898}],"compareEarnings":[{"period":"1week","weight":0.0329},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0248},{"period":"6month","weight":0.0243},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.1103}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Arrowhead Pharmaceuticals, Inc.最初于1989年在南达科他州注册成立，后在特拉华州重新注册成立。该公司开发药物，通过沉默疾病的基因来治疗疑难杂症。使用广泛的RNA化学组合和高效的递送模式，该公司的疗法触发RNA干扰机制，以诱导目标基因的快速、深度和持久敲低。目前有18个Arrowhead发现的候选药物处于早期（1期）至晚期（3期）的临床试验阶段。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.009831},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.008632},{"month":3,"riseRate":0.5,"avgChangeRate":0.050374},{"month":4,"riseRate":0.5,"avgChangeRate":0.032513},{"month":5,"riseRate":0.409091,"avgChangeRate":0.01068},{"month":6,"riseRate":0.590909,"avgChangeRate":0.024487},{"month":7,"riseRate":0.590909,"avgChangeRate":0.0537},{"month":8,"riseRate":0.409091,"avgChangeRate":0.011388},{"month":9,"riseRate":0.5,"avgChangeRate":0.05187},{"month":10,"riseRate":0.434783,"avgChangeRate":-0.030917},{"month":11,"riseRate":0.521739,"avgChangeRate":0.049021},{"month":12,"riseRate":0.454545,"avgChangeRate":0.054899}],"exchange":"NASDAQ","name":"Arrowhead Research Corporation","nameEN":"Arrowhead Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arrowhead Research Corporation(ARWR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Arrowhead Research Corporation(ARWR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Arrowhead Research Corporation,ARWR,Arrowhead Research Corporation股票,Arrowhead Research Corporation股票老虎,Arrowhead Research Corporation股票老虎国际,Arrowhead Research Corporation行情,Arrowhead Research Corporation股票行情,Arrowhead Research Corporation股价,Arrowhead Research Corporation股市,Arrowhead Research Corporation股票价格,Arrowhead Research Corporation股票交易,Arrowhead Research Corporation股票购买,Arrowhead Research Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arrowhead Research Corporation(ARWR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Arrowhead Research Corporation(ARWR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}